WASHINGTON – For thousands of transgender children enrolled in Medicaid and the Children’s Health Insurance Program, a deadline is approaching. The Trump administration finalized a rule Monday that bars the use of federal funds to pay for puberty blockers, cross-sex hormone therapy, and surgical procedures for transgender youth, with coverage ending on October 13, 2026. Children currently receiving hormone therapy have a six-month transition period before their federal coverage lapses.
The Centers for Medicare and Medicaid Services cited Federal Register number 2026-16508 in announcing the prohibition, which applies to all federal Medicaid and CHIP matching funds. The rule does not prevent states from using their own money to continue covering these services, and mental health treatment for gender dysphoria remains covered under existing requirements, according to a CMS press release.
Seventeen states currently cover some degree of gender-affirming care for children under the two federal programs, according to research cited by advocacy organizations. Whether any of those states will move to fill the coverage gap with state appropriations is a question the rule leaves entirely to state legislatures.
Health and Human Services Secretary Robert F. Kennedy Jr. announced the rule in language stripped of medical neutrality. “Today, we are ending federal taxpayer funding for sex-rejecting procedures on children,” he said. CMS Administrator Dr. Mehmet Oz, the former television physician who now oversees the agency, said “children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits.”
The framing conflicts with the stated positions of every major pediatric and psychiatric medical organization in the United States. The American Academy of Pediatrics, the American Medical Association, and the American Psychological Association all recognize gender-affirming care as evidence-based treatment for gender dysphoria in minors, and have consistently argued that restricting access causes measurable psychological harm. The CMS rule cited the United Kingdom’s Cass Review and a 2025 HHS report as evidence that these interventions carry weak scientific support, a characterization disputed by major American medical associations.
The Cass Review, a systematic analysis commissioned by England’s National Health Service and published in 2024, examined clinical evidence for gender-affirming interventions in minors and recommended a more cautious approach rather than outright prohibition. Several professional bodies and journal editors criticized the review’s methodology after its release. Its invocation by the Trump administration to justify a complete funding ban represents a policy conclusion that the review’s own authors did not endorse.
Kelley Robinson, president of the Human Rights Campaign, described the rule in categorical terms. “Every young person is entitled to the health care that they, their parents, and their medical providers agree that they need,” she said. “The Trump administration is terrorizing trans youth and their families with these kinds of actions, and it has to stop.” The Trevor Project, a crisis intervention organization for LGBTQ+ youth, called the rule “a dangerous and unnecessary attempt to prevent transgender and nonbinary young people from accessing the best-practice health care,” according to an HRC statement.
The HRC Foundation has filed a related class action lawsuit against the Office of Personnel Management over coverage restrictions in Federal Employee Health Benefits plans, a parallel legal action targeting the administration’s posture toward transgender healthcare across federal programs. Whether a direct legal challenge to Monday’s CMS rule will follow is unclear; advocacy organizations have signaled they are reviewing options.
This is not the first time the Kennedy-led HHS has moved against federal healthcare funding through administrative action. In July, the department froze over a billion dollars in Medicaid reimbursements to California and Minnesota, citing a fraud review that neither state said it had documentation for. Both states mounted legal challenges; the dispute remains unresolved.
The broader pattern has accelerated this year. Eastern Herald reported in July that the Trump administration had effectively dismantled AHRQ, the federal body charged with producing the evidence base for American medical practice, by distributing less than $15 million of the $345 million Congress had allocated. The administration is simultaneously reducing the production of independent medical evidence and invoking government-commissioned research to override broader scientific consensus.
The state-level implications are substantial. Seventeen states have built Medicaid and CHIP programs that include gender-affirming services for minors. Under the new rule, federal matching funds for those services disappear, though states may continue with their own appropriations. In states where legislatures have been hostile to transgender healthcare access, the withdrawal of federal dollars may be sufficient to end coverage without further legislation.
The same legal questions have a prior chapter. When the Sixth Circuit Court of Appeals upheld Tennessee’s gender-affirming care ban in 2023, the first federal appellate ruling to sustain such a restriction, legal observers warned that a Supreme Court ruling could reshape the entire landscape. That ruling eventually came. Monday’s CMS rule operates in the administrative space, but legal challenges to its procedural basis could emerge from the states most affected.
CMS set no timetable beyond the October 13 effective date and the six-month transition period for current hormone therapy patients. The rule contains no estimate of the number of children who will lose coverage, no mechanism for tracking affected individuals, and no provision for medical emergencies or hardship exceptions. For families navigating those gaps, the October deadline is not administrative. It is medical.
